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Background: Non-specific chronic back pain (CBP) is often accompanied by psychological trauma, but treatment
for this associated condition is often insufficient.
Nevertheless, despite the common co-occurrence of pain and psychological trauma, a specific trauma-focused
approach for treating CBP has been neglected to date. Accordingly, eye movement desensitization and
reprocessing (EMDR), originally developed as a treatment approach for posttraumatic stress disorders, is a promising
approach for treating CBP in patients who have experienced psychological trauma.
Thus, the aim of this study is to determine whether a standardized, short-term EMDR intervention added to
treatment as usual (TAU) reduces pain intensity in CBP patients with psychological trauma vs. TAU alone.
Methods/design: The study will recruit 40 non-specific CBP patients who have experienced psychological trauma.
After a baseline assessment, the patients will be randomized to either an intervention group (n = 20) or a control group
(n = 20). Individuals in the EMDR group will receive ten 90-minute sessions of EMDR fortnightly in addition to TAU. The
control group will receive TAU alone. The post-treatment assessments will take place two weeks after the last EMDR
session and six months later.
The primary outcome will be the change in the intensity of CBP within the last four weeks (numeric rating scale 0–10)
from the pre-treatment assessment to the post-treatment assessment two weeks after the completion of treatment.
In addition, the patients will undergo a thorough assessment of the change in the experience of pain, disability,
trauma-associated distress, mental co-morbidities, resilience, and quality of life to explore distinct treatment
effects. To explore the mechanisms of action that are involved, changes in pain perception and pain processing
(quantitative sensory testing, conditioned pain modulation) will also be assessed.
The statistical analysis of the primary outcome will be performed on an intention-to-treat basis. The secondary
outcomes will be analyzed in an explorative, descriptive manner.
Discussion: This study adapts the standard EMDR treatment for traumatized patients to patients with CBP who
have experienced psychological trauma. This specific, mechanism-based approach might benefit patients.
Trial registration: This trial has been registered with ClinicalTrials.gov (NCT01850875).
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Chronic pain conditions of the musculoskeletal system are
common and have high socioeconomic relevance [1-3].
This is especially true for pain conditions with widely un-
known pathogenesis, such as non-specific chronic back
pain (CBP). In addition prevalence as well as the demand
for consultation and treatment increases [4,5], thus caus-
ing high direct and indirect costs [1-3,6]. Despite high
prevalence, CBP remains poorly understood and predom-
inantly unspecific and inadequately treated.
Further, CBP is often complicated by the presence of
mental co-morbidities, but treatment for this association
remains insufficient. An important comorbidity that has
been neglected so far is the role of psychological trauma
in the development and maintenance of CBP. Traumatic
events have higher prevalence rates in CBP patients as
compared to pain-free controls or other diseases [7,8].
Between 10% and 50% of patients receiving tertiary care
treatment for chronic pain have symptoms according to
psychological trauma and posttraumatic stress disorder
[9]. Moreover, chronic pain is associated with higher ex-
posure to psychological trauma [10,11]. Contrary, only
23.8% of the German population reports a traumatic ex-
perience (fulfilling DSM-IV A criteria) and only 2.9%
have diagnoses of a posttraumatic stress disorder [12].
Concerning traumatic experiences it was suggested that
multiple traumas have a cumulative effect on physical
health, including back pain and that the impact of the
trauma on health may be independent of the develop-
ment of a posttraumatic stress disorder [13]. This was
supported in a prospective study that suggested that in
the transition from acute to chronic pain cumulative
trauma exposure appeared to be an independent risk
factor [14]. In addition, absence of recent adverse life
events independently predicted musculoskeletal health
in a prospective study [15].
Considering the association of chronic pain and symp-
toms of posttraumatic stress disorder a model of shared
vulnerability and mutual maintenance is discussed. The
model purposes that physiological, affective, and behav-
ioral components of psychological traumatization main-
tain and exacerbate symptoms of pain and, similarly, that
cognitive, affective and behavioral components of chronic
musculoskeletal pain maintain or exacerbate symptoms of
posttraumatic stress disorder. Some of these factors are
expected to constitute a shared vulnerability [9,16,17].
The model of mutual maintenance was partially con-
firmed in a prospective study by Jenewein et al. They
reported a mutual maintenance of posttraumatic stress
symptoms and pain intensity within the first six months,
but, at 12-month follow-up pain intensity was significantly
influenced by posttraumatic stress symptom, whereas such
symptoms of traumatization were no longer influenced by
pain intensity [18].Concerning treatment of CBP [19-24] or psychological
trauma [25-28] there are many guidelines. In spite of the
high comorbidity of psychological trauma and pain, none
of the guidelines for neither chronic pain nor psycho-
logical trauma incorporates the other, except the Expert
Consensus Guideline Series for treatment of posttraumatic
stress disorder [29]. Surprisingly, this guideline considers
comorbid chronic pain only in the section of medical
treatment.
Getting back to the before mentioned specific mechanism-
based treatment approach, even if trauma-focused
psychotherapy has been shown to be effective in the
treatment of psychological trauma, the efficacy of trauma-
focused psychotherapy in patients with chronic pain and
previous psychological trauma as well as the underlying
mechanisms have not yet been investigated in depth so
far. However, there are some hints that this might be
a promising approach [30-33]. The same is true for
treatment of pain. It is not known whether such common
treatment approaches are effective in patients with co-
morbid psychological trauma. This is important because
research shows that patients with anxiety disorders and
high comorbid pain interference have a lower likelihood
of responding to treatment than patients without pain
interference [34]. Therefore, research in regard to treat-
ment of chronic pain with comorbid psychological
trauma is necessary. Moreover, recent studies indicate
that trauma-focused treatment approaches can successfully
reduce comorbid symptoms also in non-posttraumatic
stress symptomatology in which trauma is judged to be of
causative significance [35].
A psychological first line treatment for psychological
trauma, that has been proven to be efficacious, is eye
movement desensitization and reprocessing (EMDR)
[25,28,36-38]. Although EMDR was originally developed
for individuals who had experienced psychological trauma,
the neurobiological similarities found in patients who suf-
fer from posttraumatic stress symptoms and chronic pain
disorders encouraged scientists to explore the utilization
of EMDR in the treatment of chronic pain, even in the
absence of psychological trauma. Accordingly, there is
an increasing amount of literature regarding the use of
EMDR in the treatment of chronic pain.
Several studies report that EMDR is able to reduce
pain intensity or even eliminate pain completely in pa-
tients with different pain disorders (e.g., phantom limb
pain, fibromyalgia, and headache) [39]. Furthermore,
EMDR has been found to improve pain coping abilities
and to facilitate relaxation abilities that finally results in
the reduction of pain and pain-related attitudes and
beliefs [40].
However, until now there have predominantly been
case-reports and case-series and none of them focused on
CBP. Moreover, though there is first evidence that EMDR
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the underlying mechanisms still remain unclear.
Accordingly, we designed a randomized controlled
trial on change in pain intensity by EMDR-treatment in
patients suffering from chronic non-specific back pain
and previous psychological trauma. In addition, our core
study is expanded by a comprehensive neurobiological
and psychosocial assessment to explore potential under-
lying mechanisms.
Therefore, the purpose of the present study is twofold:
1.) To determine whether a 10-session standardized
EMDR short-term intervention in addition to
treatment as usual (TAU) reduces pain intensity in
CBP patients with experienced psychological trauma
vs. TAU alone, and
2.) to explore additionally potential underlying
mechanisms.
Methods and design
This study is part of the consortium ‘Localized and
Generalized Musculoskeletal Pain: Psychobiological Mech-
anisms and Implications for Treatment’ [41] funded by the
German Federal Ministry of Research and Education
(01EC1010A-F). More details concerning LOGIN can be
found elsewhere [41-43]. This report is part of subproject
number six (SP6; 01EC1010A) ‘Subgroups Characterised
by Psychological Trauma, Mental Co-morbidity, and Psy-
chobiological Patterns and Their Specialised Treatment’
[43]. This trial has received ethics approval from the
Ethics Committee Heidelberg (approval No. S-261/2010),
and is registered within clinical trails.gov (NCT01850875).
All participants must provide written informed consent.
Design
The study is designed as a randomized controlled trial
with two parallel arms (see Figure 1). Forty patients will
be randomized to either the treatment group (n = 20) or
the control group (n = 20). The treatment group will
receive EMDR in addition to TAU. The control group
will receive TAU alone.
Participants
Participants will be recruited from the southwestern
district “Rhein-Neckar” of Germany, through subproject
six [43] of the LOGIN consortium. Patients will be of-
fered enrolment, when in addition to CBP they add-
itionally fulfill the criteria for experienced psychological
trauma (see Table 1). Recruitment will be done consecu-
tively until a sample size of n = 40 patients is reached
(control group: n = 20; intervention group: n = 20).
Randomization will be done centrally with the established
randomization program RANDI2 [44,45] after patient
inclusion by an independent person not involved intreatment or assessment. Allocation concealment will be
ensured, as this person will not release the randomization
code until the patient has been recruited into the trial,
which takes place after all baseline assessments have been
completed.
Outcome assessments will be conducted by an assessor
blind to treatment allocation. An employee outside the re-
search team will feed data into the computer in separate
datasheets so that the researchers can analyze data with-
out having access to information about the allocation.
Inclusion and exclusion criteria
Diagnosis of non-specific chronic back pain and psycho-
logical trauma is validated within LOGIN subproject six.
For details see [43]. Briefly, patients must report more
than 44 days of low back pain within at least the last three
months (=CBP). Then, to verify inclusion and exclusion
criteria (Table 1), all participants will be questioned about
their past medical history and about co-morbidities. In
addition, patients will also receive a physical examination
(including blood tests and if indicated further technical
investigations such as x-ray or MRI) that attaches special
importance to findings which indicate a specific origin of
back pain. Therefore the “red flags” (hints for the presence
of serious pathology according to the Agency for Health
Care Policy and Research Low Back Guidelines [47]) will
be considered and former medical reports and discharge
letters will be taken into account whenever available. In
case of signs for serious pathological findings, participants
will be excluded and a further investigation will be
advised.
Psychological trauma will be diagnosed with the
German Version of the Posttraumatic Distress Scale
(PDS-D) [46]. Patients who at least answer one trauma
item positive will be classified as patients with experi-
enced psychological trauma. All other patients will be
classified as patients without psychological trauma.
For details see [43].
Participants that meet all the inclusion criteria will
have the trial explained to them in detail and then be
asked to provide written informed consent before being
enrolled into the trial.
Description of intervention
All the participants will continue to receive their usual
routine care (e.g., general support and advice, physiother-
apy, simple analgesics for their symptoms) from their own
general practitioners and other healthcare providers in
accordance with the guidelines for the treatment of CBP
in Germany [19].
In addition to TAU, the participants assigned to the
EMDR intervention group will receive a manualized
outpatient intervention that is based on the principles
of EMDR-trauma therapy [48,49] and incorporates
Figure 1 Intervention scheme. Outcome assessments will be done before randomization (T0, baseline), two weeks after intervention/treatment
as usual (T1, primary endpoint), and six months after intervention/treatment as usual (T2, follow-up). CBP: non-specific chronic back pain.
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pants will receive ten 90-minute sessions in an individual
setting. The intervention manual will be prepared in
cooperation with an expert in trauma therapy. The EMDR
treatment will be provided by EMDR-trained psycho-
logists and physicians (who have participated in an
EMDRIA-approved Basic Training program). The thera-
pists will be trained in advance specifically in the use of
EMDR for chronic pain patients and will be supervised
regularly by an EMDRIA-approved consultant. All theTable 1 Inclusion and exclusion criteria
Inclusion criteria
Diagnosis 1.) Non-specific CBP ≥ 45 days during the past three
months, and
2.) History of experienced psychological trauma*
Age At least 18 years of age
Language Fluent German language skills
Exclusion criteria
Pathology - Specific pathologies of CBP (e.g., spinal canal stenosis,
disc hernia, spondylolisthesis, infection, malignancy,
Bechterew disease, and fracture)
- Sciatica pain≥ than back pain








Planned other or ongoing psychotherapy, change in
medication in the last three months
*Psychological trauma will be assessed using the German Version of the
Posttraumatic Diagnostic Scale (PDS-D) [46]. Patients who at least answer one
trauma item positive will be classified as patients with experienced psychological
trauma. All other patients will be classified as patients without psychological
trauma. For details see [43].sessions will be video-recorded. The therapists’ treatment
fidelity will be managed by using standardized treatment
protocols and regular supervision, including monitoring
the video-recorded sessions.
Based on the theoretical rationale proposed by Carlson
and colleagues [52] and the general recommendations for
evaluating empirical EMDR studies [53], a ‘dose’ of ten
90-minute sessions given over a 20-week period was
chosen to guarantee sufficient treatment length. Although
there is currently no definitive agreement on the number
of EMDR treatment sessions required [48] and the exist-
ent literature suggests that EMDR is effective with fewer
than ten sessions (e.g., van Rood 2009 [54]), we postulate
that this number of treatment sessions will allow adequate
time for testing comparative treatments as well.
Based on the theoretical rationale proposed by Carlson
and colleagues [52], and the general recommendations
for the evaluation of empirical EMDR studies [53] a
‘dose’ of ten sessions à 90 minutes per session given over
a 20-weeks period is chosen to guarantee sufficient treat-
ment length. Even though there is currently no definitive
agreement on the number of EMDR treatment sessions
required [48], and existent literature supports EMDR
effectiveness in fewer than ten sessions (e.g., van Rood
2009 [54]), we postulate that this number of treatment
sessions would allow adequate time to test comparative
treatments as well.
Data acquisition
All the outcome assessments and the EMDR sessions
will be conducted at the Department of General Internal
Medicine and Psychosomatics, University Hospital
Heidelberg, Germany. The outcome assessments will
be performed by an independent evaluator who is
Table 2 Outcome measures
Primary outcome
Pain intensity • Numerical rating scale (NRS), ranging from 0 ‘no
pain’ to 10 ‘worst pain imaginable’ [55].
Secondary outcomes
Pain dimensions • Pain duration (number of painful days in the
last 4 weeks).
• Pain Experience Scale (SES) measures the
affective and sensory dimensions of pain [56].
Medication • Change in medication intake.
Disability • 12-Item Short Form Health Survey (SF-12)
measures health-related quality of life [57,58].
Depression and
Anxiety
• Hospital Anxiety and Depression Scale
(HADS-D) [59].
Stress/ Trauma • Change in Posttraumatic Diagnostic Scale levels
(PDS) [60].
• Dissociation symptoms questionnaire (DES/FDS-
20) for assessment of dissociative symptoms [61].




• Quantitative Sensory Testing (QST) for
assessment of all relevant aspects of the
somatosensory system including large and small
fiber function as well as signs of central




• Conditioned Pain Modulation (CPM) paradigm
for assessment of inhibitory pain modulating
mechanisms [64]. Difference in pressure pain
threshold before and after inducing CPM by a
phasic heat pain stimulus will be measured.
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baseline (T0, before randomization), two weeks after the
intervention/TAU (T1, primary endpoint), and six months
after the intervention/TAU (T2, follow-up). The physical
examination and the clinical interviews will only be
conducted at baseline. The assessor will be trained at the
beginning of the study and will be observed regularly to
ensure the reliability and validity of the measures.
Outcome measures
The primary endpoint with respect to the efficacy of the
standardized short-term EMDR intervention for CBP is
the change in the intensity of back pain from T0 to T1
measured on a numeric rating scale (NRS 0–10, averaged
over four weeks). The NRS for pain intensity has proven
to be a reliable and valid instrument for assessing treat-
ment effects in pain trials [55].
The secondary outcomes, which include distinct pain
variables (mean pain duration, pain experience, and pain
intensity at T2), medication intake, health-related quality
of life (SF-12), anxiety and depression (HADS), dissoci-
ation symptoms (FDS-20), psychological resilience (RS-
11), and somatization (SCL-90R subscale somatization),
will be measured at all assessment points (T1 and T2).
In addition to the efficacy endpoints, we assess the
peripheral and central modulation of pain (quantitative
sensory testing, QST, and conditioned pain modulation,
CPM) in all the patients to explore the differences in
pain processing induced by the EMDR intervention. An
overview of the primary and secondary outcomes is
shown in Table 2.
Moreover, as part of the LOGIN study, all the partici-
pants in our study will be assessed for a shared core set
of variables, including a comprehensive assessment of
neuromodulators (plasma nerve-growth-factor, plasma
endocannabinoid and lipid levels) and the functional and
structural changes in functional neuroimaging (fMRI),
before and after treatment (for further details, see [43]).
Assessment of safety
Serious adverse events (SAEs) will be documented and
reported casuistically.
Sample size estimation
The sample size calculation is based on the primary effi-
cacy endpoint: change in the pain intensity (numeric rat-
ing scale 0–10) after the intervention (T1). The expected
effect size for our trial is derived from previous evidence
about the effect of EMDR therapy for chronic pain
patients.
The two controlled trials currently available are charac-
terized by high effect sizes with Hedges’ g ranging
from −1.12 [65] to −6.87 [66]. Based on this data, an
effect size of at least 1.0 can be expected after ten sessionsof treatment. A sample size of 17 patients in each group
will have 80% power to detect an effect size of 1.0 using
a t-test for independent groups with a 0.05 two-sided
significance level. Based on comparable studies and our
own experience with pain trials, we expect a 20%
drop-out rate. Therefore, a total sample size of 40 patients
is required for the study. The patients who are lost to
follow up and/or non-compliant patients will be handled
using an intention-to-treat procedure.
Statistical analyses
The data analysis will follow the evaluation standards for
experimental study designs with control groups, using
descriptive methods as well as inferential statistics. The
data will be analyzed using an intention-to-treat approach.
Because of the small sample size in the study, multiple
imputation (the gold standard for handling missing values)
is not appropriate. Therefore, only complete cases will be
used in the final analysis. Dropouts, withdrawals and miss-
ing values will be analyzed in detail; different techniques
will be used to assess them, and these techniques will be
compared using sensitivity analyses. Descriptive statistics
will be presented as the means and standard deviations for
the continuous variables and absolute numbers and
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naires will be processed in accordance with questionnaire
manuals.
The differences between the change scores of the pa-
tient groups will be analyzed using independent t-tests.
Moreover, potential negative effects will be reported de-
scriptively (e.g., pain intensity after the trauma-focused
intervention > pain intensity before the trauma focused
intervention). Preliminary effect sizes will be estimated
using Cohen’s d.
Pre-processing analyses and statistical analyses of
quantitative sensory testing data will be performed
according to the protocol used by Rolke et al. [63]. To
quantify conditioned pain modulation, the pressure pain
threshold before a phasic heat stimulus will be subtracted
from the pressure pain threshold after the phasic heat
stimulus. A negative value indicates an analgesic effect
due to CPM [64].Discussion
Although CBP is often accompanied by psychological
trauma and posttraumatic stress symptoms, a specific
trauma-focused approach for this subgroup of CBP cases
has been a neglected issue to date. Eye movement
desensitization and reprocessing, originally developed as
a short-duration, high-efficiency treatment approach for
posttraumatic stress symptoms, is a promising approach
for treating CBP in patients who have experienced psycho-
logical trauma. The preliminary evidence suggests that
EMDR treatment may benefit patients with medically un-
explained somatic symptoms [54]. To date, several uncon-
trolled studies using EMDR have been conducted for a
multitude of various pain syndromes [40,66-70]. These
studies suggest that EMDR may be a safe and promising
treatment option for chronic pain conditions.
However, most of the research conducted thus far has
been preliminary in nature and characterized by small
sample sizes, heterogeneous patient groups, the lack of
randomization and the absence of adequate control
groups. Moreover, to our knowledge, none of these studies
have evaluated the efficacy of EMDR in patients suffering
CBP. Thus, there is an urgent need for further exploration
of the efficacy of EMDR for treating chronic pain patients
using well-designed studies with standardized EMDR in-
terventions of sufficient treatment length and adequate
control groups. Accordingly, we designed this randomized
controlled trial on the effects of EMDR treatment for non-
specific chronic back pain patients who have experienced
psychological trauma to determine whether a standardized
short-term EMDR intervention reduces pain intensity in
this subgroup of CBP patients. Because this is the first
randomized controlled trial on this topic, the results of
this study will encourage a more specific trauma-focusedtreatment approach, especially for the pain patients who
have experienced psychological trauma.
However, although there is preliminary evidence that
EMDR is effective and useful for the treatment of chronic
pain, the underlying mechanisms remain unclear. There-
fore, our core study will be supplemented by a compre-
hensive neurophysiologic and psychosocial assessment to
explore these mechanisms of action.
Notably, the study is part of the LOGIN consortium
study [41]. LOGIN comprises seven subprojects, including
basic and applied research as well as preclinical and clin-
ical projects utilizing a wide variety of research methods.
As part of this consortium study, all the participants in
our study will additionally be assessed for a shared core
set of variables to investigate similar pathogenetic mecha-
nisms. This approach enables us to expand our explor-
ation of the underlying mechanisms by conducting a
comprehensive assessment of systemic neuromodulators
(plasma nerve-growth-factor, plasma endocannabinoid
and lipid levels) and the functional and structural changes
with functional neuroimaging (fMRI) before and after
treatment and to explore the differences in pain process-
ing induced by the EMDR intervention. This approach will
be supported by the translational aspects of LOGIN. Thus,
using the synergy of the different subprojects, the timely
translation, implementation and dissemination of the re-
sults will be guaranteed.
The findings of this study might contribute to improve-
ments in the treatment of patients suffering from CBP as
well as to better understanding of the mechanisms of
action underlying EMDR in chronic pain patients.Competing interest
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